CryoSave AG’s and Salveo Life Sciences S.A.’s principal activity is the collection, processing and storage of adult human stem cells from umbilical cord blood and the umbilical cord itself. The principal activity of the other subsidiaries is the marketing and promotion of this service, except for Output Pharma Services GmbH.
Genoma is the Group’s second business unit active in the fields of proteomics and genomic predictive medicine. This business has been introduced end 2014.
The Group’s R&D division, The Cell Factory, is the third business unit of the Group. The Cell Factory implements its own proprietary new technology for clinical grade production of autologous mesenchymal and stromal stem cells.
Name of subsidiary directly held by ESPERITE N.V. | Place of incorporation |
CryoSave AG | Switzerland |
Genoma SA | Switzerland |
Salveo Life Sciences SA | Switzerland |
Cryo-Save Italia Srl. | Italy |
Crio-Cord S.L. | Spain |
Cryo-Save Serbia d.o.o. Beograd | Serbia |
Cryo-Save Hungary Kft. | Hungary |
Tissue Bank Cryo Center Bulgaria AD | Bulgaria |
Cryo-Save GmbH | Germany |
Cryo-Save Labs NV | Belgium |
Cryo-Save Stammzelltechnologie GmbH | Austria |
Fagite S.A. | Greece |
Cryo-Save France S.A.S. | France |
VSB Services Ltd. | Hungary |
InKaryo Corporation | USA |
Cryo-Save USA, Inc. | USA |
Stichting Cryo-Save* | The Netherlands |
Stichting Cryo-Save Research* | The Netherlands |
Output Pharma Services GmbH | Germany |
Cryo-Save Portugal Lda. | Portugal |
Cryo-Save South Africa Ltd. | South Africa |
Cryo-Save CZ s.r.o. | Czech Republic |
* ESPERITE N.V. controls this entity.